Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | ADK | P55263 | 1/20 | 0.48 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5855000 | 0.98 | CSNK1A1 (0.47) | CSNK1A1TYRO3DYRK1BPDE4APDE4B | |
| SCHEMBL945727 | 0.82 | CSNK1A1 (0.53) | CSNK1A1TYRO3DYRK1BPDE4APDE4B | |
| SCHEMBL20497275 | 0.81 | LRRK2 (0.46) | CSNK1A1TYRO3DYRK1BPDE4APDE4B | |
| SCHEMBL9287236 | 0.80 | NISCH (0.64) | CSNK1A1TYRO3DYRK1BMTORADK | |
| SCHEMBL5271260 | 0.80 | CSNK1A1 (0.38) | CSNK1A1TYRO3DYRK1BPDE4APDE4B | |
| SCHEMBL14886257 | 0.78 | NISCH (0.61) | CSNK1A1TYRO3DYRK1BMTORADK | |
| SCHEMBL1239841 | 0.78 | ADRA2A (0.46) | CSNK1A1TYRO3DYRK1BPDE4APDE4B | |
| SCHEMBL8538740 | 0.78 | NISCH (0.46) | PDE4APDE4BPDE4CPDE4DMTOR | |
| SCHEMBL4765948 | 0.77 | LRRK2 (0.44) | CSNK1A1TYRO3DYRK1BPDE4APDE4B | |
| SCHEMBL5012098 | 0.77 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023237381-A1 | PROCESS FOR THE SYNTHESIS OF POLYETHYLENES OR COPOLYMERS OF ETHYLENE AND 1,3-DIENE HAVING A TERMINAL KETONE FUNCTION | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2023-12-14 | — | — | WO | disclosed |
| CN-116829353-A | Epoxy resin composition, cured product thereof, and laminate | DIC株式会社 | 2023-09-29 | — | — | CN | disclosed |
| CN-116217546-A | Electronic transmission layer material with phenanthroimidazole as core skeleton and organic electroluminescent diode and preparation method thereof | 青岛科技大学 | 2023-06-06 | — | — | CN | disclosed |
| US-10617685-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-04-14 | — | — | US | disclosed |
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-21 | — | — | US | disclosed |
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1635813-A4 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7544717-B2 | 2-amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| CN-100384824-C | Acetyl 2-hydroxy-1, 3-diaminoalkanes | PHARMACIA & UPJOHN CO LLC (US) | 2008-04-30 | — | — | CN | disclosed |
| US-6610701-B2 | For therapy and prophylaxis of blood coagulation and cardiovascular disorders | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002064211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064140-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064559-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-0358284-B1 | Derivatized alkanolamines as cardiovascular agents | SCHERING AG (DE) | 1997-08-20 | — | — | EP | disclosed |
| US-5420148-A | SYNERGISTIC MIXTURE OF A 2-CYANOBENZIMIDAZOLE DERIVATIVE AND A KNOWN FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1995-05-30 | — | — | US | disclosed |
| US-5051423-A | Derivatized alkanolamines as cardiovascular agents | SCHERING AG (DE) | 1991-09-24 | — | — | US | disclosed |
| EP-0358284-A2 | Derivatized alkanolamines as cardiovascular agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-03-14 | — | — | EP | disclosed |
| WO-1990000548-A2 | DERIVATIZED ALKANOLAMINES AS CARDIOVASCULAR AGENTS | SCHERING AKTIENGESELLSCHAFT BERLIN AND BERGKAMEN (DE) | 1990-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | BACE1, BACE2, APP | CSNK1A1 428/4885TYRO3 3836/4885DYRK1B 3612/4885 |
| US-10617685-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | AR, NR5A1, BRCA1 | CSNK1A1 649/4885TYRO3 4397/4885DYRK1B 4075/4885 |
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | CSNK1A1 3419/4885TYRO3 1469/4885DYRK1B 4309/4885 |
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | AR, NR5A1, BRCA1 | CSNK1A1 649/4885TYRO3 4397/4885DYRK1B 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.